Site search
2880 results for '' found
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Pr
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Pr
/
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Rel
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Rel
/
Assessment of MEchaNical Dyssynchrony versus standard selection on clinical response in candidates for Cardiac Resynchronization Therapy – The AMEND-CRT Trial (NCT04225520)
Assessment of MEchaNical Dyssynchrony versus standard selection on clinical response in candidates for Cardiac Resynchronization Therapy – The AMEND-CRT Trial (NCT04225520)
/
Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial (ACTRN12622001366741)
Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial (ACTRN12622001366741)
/
A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy (NCT05109091)
A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy (NCT05109091)
/
A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-invasively diagnosed nonalcohol steatohepatitis (NASH)/ Nonal
A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-invasively diagnosed nonalcohol steatohepatitis (NASH)/ Nonal
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [NASH]/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [NASH]/
/
A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH) and fibrosis. (
A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH) and fibrosis. (
/
A randomised, double-blind, placebo-controlled, multicenter, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of rozanolixizumab in adult study participants with leucine-rich
A randomised, double-blind, placebo-controlled, multicenter, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of rozanolixizumab in adult study participants with leucine-rich
/
A Phase II observational study: autologous haematopoietic stem cell transplantation for highly active treatment resistant multiple sclerosis (ACTRN12616000151437)
A Phase II observational study: autologous haematopoietic stem cell transplantation for highly active treatment resistant multiple sclerosis (ACTRN12616000151437)
/